Wednesday, 19 Feb 2020

You are here

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Investigators performed a retrospective cohort review of 77 sJIA patients enrolled from 15 Italian centers who were treated with either anakinra (ANA) and canakinumab (CAN). The mean age of these patients was 12.7 years and mean sJIA disease duration was 4 years.

The retention rate of these IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9%, 59.5%, 53.%5, and 53.5%, respectively.

While the differences were not statistically different between ANA and CAN, the cumulative survival (retention) trended in favor of CAN, without concomitant DMARD (p = 0.056) and with concomitant DMARD use (p = 0.058).  Survival was significantly better with first time use of an IL-1 inhibitor.

Adverse events were significantly more frequent in those previously treated with biologic drugs (p = 0.038) compared to biologic naive patients.

Those with a higher risk of IL-1 inhibitors withdrawal included patients previously treated with other biologics (HR = 3.357 [CI: 1.341-8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186-7.435], p = 0.020).

These data suggest an excellent overall for both ANA and CAN, especially when used first line to manage sJIA.

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.

Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi.